CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向神经生长因子：肿瘤的阿喀琉斯之踵？
英文原题：Targeting nerve growth factor: an Achilles' heel for tumors?
查看英文原题
Targeting nerve growth factor: an Achilles' heel for tumors?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
肿瘤吸引神经支配的能力是肿瘤进展和免疫逃逸的重要因素，其中交感神经系统发挥主要作用。交感神经释放的儿茶酚胺激活肿瘤细胞上的肾上腺素能受体，促进肿瘤生长并增强其治疗抵抗；激活免疫细胞上的肾上腺素能受体则会诱发肿瘤微环境中的免疫抑制活性。肿瘤细胞产生的神经生长因子（NGF）是促进肿瘤神经支配的关键因素，因此是有前景的新型治疗靶点。在本述评中，我们介绍Yang等人近期一项研究，该研究考察了分泌NGF单链可变片段（scFv）的嵌合抗原受体（CAR）T细胞，以及CAR-T 细胞中和NGF对其功能和肿瘤微环境重塑的影响。这项工作表明，可将肿瘤来源的生存因子转化为肿瘤弱点，从而增强抗肿瘤免疫活性。
展开英文摘要原文
A tumor's ability to attract innervation is a critical factor in tumor progression and immune escape, with the sympathetic nervous system playing a major role. Catecholamines released by sympathetic nerves activate adrenergic receptors on tumor cells, enhancing growth and resistance to therapies, while activation of adrenergic receptors on immune cells triggers immunosuppressive activity in the tumor microenvironment. Nerve growth factor (NGF) produced by tumor cells is a key driver of tumor innervation, making it a promising target for novel therapeutic strategies.
In this commentary, we highlight a recent study by Yang et al , which examines NGF single-chain variable fragment (scFv)-secreting chimeric antigen receptor(CAR) T cells and the impact of NGF neutralization by CAR T cells on CAR T-cell function and the remodeling of the tumor microenvironment. This work shows that we may be able to exploit a tumor-derived survival factor as a vulnerability and a means to enhance antitumor immune activity.
论文信息
- 作者
- Repasky E、Mohammadpour H
- 第一作者单位
- Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org.United States
- 通讯作者单位
- Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA elizabeth.repasky@RoswellPark.org Hemn.Mohammadpour@RoswellPark.org.United States
- 期刊
- Journal for immunotherapy of cancer2025 May 2
- 原文标识
- PubMed 40316307 · DOI 10.1136/jitc-2025-011609
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →